KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Cash Flow (2016 - 2025)

Travere Therapeutics' Net Cash Flow history spans 15 years, with the latest figure at -$17.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 175.71% year-over-year to -$17.5 million; the TTM value through Dec 2025 reached $32.2 million, up 2432.15%, while the annual FY2025 figure was $32.2 million, 2432.15% up from the prior year.
  • Net Cash Flow reached -$17.5 million in Q4 2025 per TVTX's latest filing, down from $35.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $98.8 million in Q1 2023 to a low of -$132.5 million in Q4 2023.
  • Average Net Cash Flow over 5 years is -$18.8 million, with a median of -$12.5 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: surged 1275.15% in 2021, then tumbled 218.9% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$41.6 million in 2021, then tumbled by 171.05% to -$112.9 million in 2022, then dropped by 17.39% to -$132.5 million in 2023, then skyrocketed by 117.43% to $23.1 million in 2024, then crashed by 175.71% to -$17.5 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Net Cash Flow are -$17.5 million (Q4 2025), $35.6 million (Q3 2025), and $11.3 million (Q2 2025).